دورية أكاديمية

Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells

التفاصيل البيبلوغرافية
العنوان: Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells
المؤلفون: Huang, Chin-Shiu, Lyu, Shih-Chieh, Hu, Miao-Lin
المساهمون: Wei Chun Wang
سنة النشر: 2012
المجموعة: National Chung Hsing University Institutional Repository - NCHUIR / 國立中興大學
مصطلحات موضوعية: β-Ionone, Sorafenib, Metastasis, Focal adhesion kinase, Tissue inhibitor matrix metalloproteinase
الوصف: The combination of anti-cancer drugs with nutritional factors is a potential strategy for improving the efficacy of chemotherapy, particularly for hepatocellular carcinoma because its conventional therapies are mostly ineffective. Using a highly invasive hepatoma SK-Hep-1 cell line, we investigated the possible synergistic antimetastatic efficacy of a combination of sorafenib (SF), a multi-kinase inhibitor, and β-ionone (BI), a precursor of carotenoids. We found that SF (1 μM) in combination with BI (1 μM) synergistically inhibited cell invasion and additively inhibited cell migration, especially at 48 h of incubation. Mechanistically, the combination of SF and BI was found to decrease the protein expression of focal adhesion kinase (FAK) and Rho, and to enhance the protein expression of tissue inhibitor matrix metalloproteinase (TIMP)-1 and TIMP-2. In addition, the combination of SF and BI inhibited the activity of matrix metalloproteinase (MMP)-2 and MMP-9 and decreased the phosphorylation of FAK and of Rac1 proteins. Importantly, SF enhanced the suppressing effect of BI (1–50 μM) on the viability of SK-Hep-1 cells, but not on murine hepatic BNL CL.2 cells, indicating the selective cytotoxicity of this combination on tumor cells. The combination of SF and BI could be a potential therapeutic strategy against human hepatoma cells.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: #PLACEHOLDER_PARENT_METADATA_VALUE#; Investigational New Drugs, Volume 30, page(s) 1449–1459.; http://dx.doi.org/10.1007/s10637-011-9727-0Test; http://hdl.handle.net/11455/62221Test
DOI: 10.1007/s10637-011-9727-0
الإتاحة: https://doi.org/10.1007/s10637-011-9727-0Test
http://hdl.handle.net/11455/62221Test
حقوق: none
رقم الانضمام: edsbas.AB9C5CF4
قاعدة البيانات: BASE